BioSpace News Archive

Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response was Not Reached

Imperative Care, Inc., a company singularly dedicated to answering unsolved problems in stroke, announced that Matthew Garrett has been appointed as the company’s Chief Financial Officer.

Rooted in a commitment to dermatology, La Roche-Posay has been a trusted source for skincare for over 40 years.

Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced the appointment of Dekel Gelbman as its senior vice president of Business Development and Strategy.

Athletico Physical Therapy today announced Skip Bourdo as the organization’s new Chief Operating Officer. Bourdo will lead the Field Operations across its platform of 529 clinics, including the organizatio

Brain Scientific Inc., a neurology-focused medical device and software company, has entered into an agreement with Europe’s leading certification and compliance company AFINA s.r.o.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and a network of high-complexity labs to deliver saliva-based COVID-19 testing.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 72 new employees with a grant date of November 15, 2020 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stoc

Product Lifecycle Management is used for maximizing the revenue generation capabilities of pharma companies.

The plasma therapy market is likely to gain momentum in the coming years on account of the increasing cases of sports injuries worldwide.